BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
Earnings
BioNexus Gene Lab's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of BioNexus Gene Lab's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
BioNexus Gene Lab has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When BioNexus Gene Lab puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases BioNexus Gene Lab filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Update
- News
- News
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- News
See a number that looks wrong?